Advanced Code injection

Ontario Industry Updates

BDC Thrive Lab launches $35m co-investment phase

Business Development Bank of Canada (BDC), Canada's bank for entrepreneurs, recently announced the details around the Thrive Lab's first phase, which will be built around a co-investment model with like-minded partners focused on supporting women-led businesses at the earliest stages of development.

 BDC is actively seeking partners with a proven history of supporting women entrepreneurs and those committed to providing additional capital, or "sweat equity" in the form of time, training, or resources.

VBI Vaccines and Brii Biosciences expand Hepatitis B partnership to address prevention and treatment

VBI Vaccines recently announced the expansion of its hepatitis B (HBV) partnership with Brii Biosciences. This is a step towards combatting HBV by making improvements in preventing and treating patients with HBV. 

Adam Buckley, VBI's Senior Vice President, Business Development, is a member of the OBIO® Board of Directors.

Epineuron announces launch of FDA clinical trial for bioelectronic therapy for nerve regeneration

Epineuron recently announced the official launch of an FDA clinical trial for PeriPulse™, breakthrough solution for bioelectronic nerve regeneration therapy. Building on robust research led by its scientific and clinical advisory board, the company has successfully obtained regulatory approval to conduct a multicentre clinical trial in traumatic acute nerve injury for this breakthrough therapy.

Epineuron is an alumnus of the BDSP™, CAAP®, HealthMINT™, H2BB™, and WiHI programs, and presented at the OBIO® Investment Summit.

Recursion announces collaboration and $50 million investment from NVIDIA

Recursion recently announced the collaboration and $50 million investment from NVIDIA, bringing together the expertise of both companies. The company also announced plans to accelerate development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services.

Ditch Labs secures $3.25 million to treat nicotine addiction with tech

Armed with $3.25 million CAD in seed funding, Montréal-based healthtech start-up Ditch Labs wants to help smokers wean themselves off nicotine with its dual hardware-software solution. Ditch Labs’ solution consists of a medical nicotine vaporizer that facilitates controlled delivery and a complementary app that provides personalized support, progress tracking, and behavioural interventions. With this combo, the startup aims to address the physiological and psychological impacts of nicotine addiction simultaneously.

Ditch Labs presented at the OBIO® Investment Summit.

Sunnybrook’s Medventions program expands to Atlantic Canada

Sunnybrook Research Institute (SRI) and INOVAIT recently announced the expansion of Medventions, Sunnybrook’s flagship fellowship training program in health technology innovation. The second Canadian site will be in Nova Scotia, led by the Nova Scotia Health Innovation Hub in Halifax.

 The Medventions fellowship program equips budding health technology leaders with the skills and expertise to address current issues within healthcare and grow medical technology companies. Through this new partnership, aspiring entrepreneurs and innovators from Atlantic Canada will gain hands-on entrepreneurial and intrapreneurial experiences in healthcare innovation and technology commercialization.

Recursion opens its Canadian headquarters in Toronto

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, recently celebrated the opening of their Toronto site, which will serve as the headquarters for Recursion Canada. In total, Recursion currently employs approximately 100 highly skilled employees in Canada, and the Toronto site is Recursion’s largest site outside of its global headquarters in Salt Lake City, Utah.

Oncoustics among Google’s first North America-wide cloud accelerator cohort

Oncoustics is among Google's recently unveiled cohort of 12 start-ups participating in the first installation of its cloud accelerator for start-ups in North America. Oncoustics CEO Beth Rogozinski said that as part of the program, the company aims to hone its ability in scaling machine learning environments and processes for the purpose of developing multiple new diagnostic products.

Oncoustics is an OBIO® member, an alumnus of the BDSP™, CAAP® and EAHN ™ programs, and presented at the OBIO® Investment Summit.

CABHI funds over $1.9 million in latest cohort of healthcare innovations for older adults and caregivers

The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, recently announced funding of over $1.9 million to support the development and validation of 40 innovations aimed at improving the quality of life for older adults, people living with dementia, and caregivers. The latest cohort features innovation projects covering CABHI's priority themes of caregiver support, aging in place, care coordination and navigation, and cognitive and mental health.

M&A activity in the medical devices industry in Canada increased by 14% in Q1 2023

According to GlobalData’s Deals Database, eight M&A deals were announced in Q1 2023, worth a total value of $150.9m in the Canadian medical devices industry.

 In value terms, M&A activity in Canada increased by 1763% in Q1 2023 compared with the previous quarter’s total of $8.1m and rose by 128% as compared to Q1 2022. Related deal volume increased by 14% in Q1 2023 versus the previous quarter and was 14% higher than in Q1 2022.

Canadian manufacturers form alliance with medical device OEMs

Two Winnipeg-based companies Precision ADM and Orthopaedic Innovation Centre (OIC) are joining Tecomet and EOS forging partnerships across North America.

The partnership includes a full range of services including front-end engineering and design services, 510k approval pathways, device and machine validation, pre-clinical testing, and commercialization.

Zucara Therapeutics receives additional funding of US$2 million

Zucara Therapeutics, a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with diabetes, recently announced additional funding of US$2 million from JDRF, the leading global Type 1 diabetes research and advocacy organization. The funding will support Zucara’s planned Phase 2a study aimed at showing prevention of hypoglycemia in people with Type 1 diabetes. 

Zucara Therapeutics is an OBIO® member, is part of OBIO’s Workforce Development programs and presented at the OBIO® Investment Summit.

Trexo Robotics’ walker opens possibilities of movement for five-year old

Read this article published by CBC on how technological innovations can bring joy in the lives of children with mobility difficulties by allowing them to experience walking and improve balance. Trexo Robotics’ robotic walker opened possibilities of movement for five-year old Leo Cogger.

Trexo Robotics is an EAHN™ company and is currently working on an evaluation project with Alberta Health Services to improve the quality of life of children with disabilities and injuries.

Innovative digital treatment aims to improve quality of life for cancer survivors

The SEAMLESS Study, a clinical trial for cancer survivors, is set to investigate the effectiveness of Mobio Interactive’s mobile programme, Mindfulness-Based Cancer Survivorship (MBCS), in reducing post-treatment side-effects for cancer survivors across Canada. The study aims to enhance the psychosocial care available to survivors through the use of a low-cost, evidence-based intervention delivered remotely via the digital theragnostic platform, AmDTx.

OBIO® through its Early Adopter Health Network (EAHN™) is supporting a new CHEO Research Institute study, in collaboration with Mobio Interactive to examine the feasibility of delivering clinically validated mindfulness therapy for youth through the latter's AI-powered mobile app. Read more about the partnership here.

Innovation Factory announces innovators in i.d.e.a Fund™ cohort 2

Twenty-one companies received contributions of $630,000 from Innovation Factory, in partnership with Innovation Guelph, through Cohort 2 of the Government of Canada-supported i.d.e.a. Fund™.

 The i.d.e.a. Fund™ is a southern Ontario-focused initiative that was developed to help clean growth firms access the tools they need to succeed by providing financial and business advisory supports to develop or redesign green products, services, processes and technologies that reduce impacts to our environment and create made-in-Canada climate change solutions.

 AIMA Laboratories, an OBIO® member, is among the recipient companies.

Feldan Therapeutics secures $16.5 million series B to bring lead asset to clinical development

Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, recently announced the initial closing of a $16.5 million Series B investment. The funds will primarily be used to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.

Feldan Therapeutics presented at the OBIO® Investment Summit.

$11 million program supporting Ontario’s biotech start-ups

Eight Ontario start-ups in the health, food and agriculture and clean-tech sectors are the first round of recipients for Ontario Genomics’ BioCreate program, an $11.6-million initiative providing financial and business support to help move the province’s biotechnology scene forward.

Congratulations to AIMA Laboratories, an OBIO® member and other companies including Index Biosystems, Kraken Sense, Ceragen, BioFect Innovations, Genecis, Liven Proteins and Performance Plants on being selected for the first cohort of BioCreate!

Canadian life sciences on life support? We must stem the innovation brain drain

BY DR. MAURA CAMPBELL AND CATE MURRAY
SPECIAL TO THE GLOBE AND MAIL

Our health research and commercialization systems are in trouble – they need our attention now. We have a world-leading legacy in the life sciences. Canadians invented insulin, the pacemaker and the first Ebola vaccine. We discovered the genes that cause ALS and cystic fibrosis. Canadians are also pioneers in the field of regenerative medicine through the discovery of stem cells and how to use them to treat disease and illness.

Yet, despite our country’s ability to make groundbreaking discoveries, something happens along the way that is keeping us from realizing the full value of our research efforts. Many Canadian innovations never make it out of the lab. If they do, they end up south of the border.

As a result of poor commercialization of intellectual property, we lose not only direct economic and health benefits but indirect benefits too – specifically, attracting and retaining a skilled talent base with the passion, know-how and commitment to produce made-in-Canada health products that will ensure our country’s health security and prosperity.


Maura Campbell is the president and CEO of the Ontario Bioscience Innovation Organization.
Cate Murray is the president and CEO of the Stem Cell Network.

Providence Therapeutics announces partnership with University Health Network (UHN) for mRNA therapeutic discovery and development

Providence Therapeutics Holdings Inc., a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, recently announced its mRNA drug discovery partnership with University Health Network (UHN), ranked first on a list of Canada's top 40 research hospitals by Research Infosource Inc. and within one of the world’s top 5 hospitals for the fourth year in a row, as reported by Newsweek. This collaboration will allow Providence and UHN to develop mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases, using Providence’s proprietary mRNA platform technology.